Physician profile
Morgan E Naylor
NPI 1942734454
$8,829.03
in general payments reported to CMS, 2019-2025
24 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $1,073 · 2023: $1,828 · 2024: $3,163 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401 · Consulting Fee: $1,688 · Education: $278 · Travel and Lodging: $15.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.31 |
| Consulting Fee | $1,687.50 |
| Education | $278.33 |
| Travel and Lodging | $15.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $2,453.78 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Abbvie INC. | $1,625.48 | 2023-2025 | |
| Incyte Corporation | $965.84 | 2021-2025 | Opzelura |
| Genzyme Corporation | $577.87 | 2021-2025 | |
| Janssen Biotech, INC. | $495.16 | 2022-2025 | Tremfya |
| Ucb, INC. | $366.60 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $331.15 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $324.98 | 2022-2025 | Dupixent |
| Pfizer INC. | $293.84 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $266.82 | 2023-2025 | |
| Amgen INC. | $230.40 | 2022-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $139.51 | 2024 | Daxi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.41 | 2022-2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $122.38 | 2022 | |
| Allergan, INC. | $116.22 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $88.69 | 2023-2025 | Seysara |
| Sun Pharmaceutical Industries INC. | $67.69 | 2022-2024 | Ilumya |
| Leo Pharma INC. | $48.29 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $44.17 | 2024 | Zoryve |
| Epi Health, LLC | $42.95 | 2022 | |
| Merz North America, INC. | $24.53 | 2025 | |
| Dermavant Sciences, INC. | $23.58 | 2024 | Vtama |
| Lilly USA, LLC | $23.53 | 2022 | |
| Journey Medical Corporation | $20.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.